

# Xenograft Model Antitumor Assays

[View the current Xenograft Model Antitumor Assays InDepth page on BioPortfolio.com](http://www.bioportfolio.com/indepth/Xenograft_Model_Antitumor_Assays.html)

([http://www.bioportfolio.com/indepth/Xenograft\\_Model\\_Antitumor\\_Assays.html](http://www.bioportfolio.com/indepth/Xenograft_Model_Antitumor_Assays.html))

## Recent Publications on Xenograft Model Antitumor Assays:



- [Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action.](#)  
*PURPOSE: ART and its derivatives, clinically used antimalarial agents,...*4th October, 2008  
Key Laboratory of Nutrition and Metabolism, Institute for Nutritional- Clin Cancer Res. 2008 Sep 1;14(17):5519-30. ([DOI Direct Link](#))
- [TMTP1, a novel tumor-homing peptide specifically targeting metastasis.](#)  
*PURPOSE: Tumor metastasis continues to be the major obstacle to cancer...*4th October, 2008  
Cancer Biology Research Center, Tongji Hospital, Tongji Medical College,- Clin Cancer Res. 2008 Sep 1;14(17):5494-502. ([DOI Direct Link](#))
- [Thymidine selectively enhances growth suppressive effects of camptothecin/irinotecan in MSI+ cells and tumors containing a mutation of MRE11.](#)  
*PURPOSE: DNA synthesis inhibitors and damaging agents are widely used in...*4th October, 2008  
Institute for Cancer Studies, University of Sheffield, School of Medicine- Clin Cancer Res. 2008 Sep 1;14(17):5476-83. ([DOI Direct Link](#))
- [Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.](#)  
*PURPOSE: Soft tissue sarcoma (STS) is a rare heterogeneous malignancy....*4th October, 2008  
Department of Surgical Oncology, University of Texas, M D Anderson Cancer- Clin Cancer Res. 2008 Sep 1;14(17):5466-75. ([DOI Direct Link](#))
- [Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor \(VEGF-R\) 2 and VEGF-R3 kinase.](#)  
*PURPOSE: Vascular endothelial growth factor (VEGF)-C/VEGF-receptor 3...*4th October, 2008  
Discovery Research Laboratories II, Eisai Co. Ltd., Tokodai, Tsukuba,- Clin Cancer Res. 2008 Sep 1;14(17):5459-65. ([DOI Direct Link](#))
- [Inhibition of glioblastoma growth in a highly invasive nude mouse model can be achieved by targeting epidermal growth factor receptor but not vascular endothelial growth factor receptor-2.](#)  
*PURPOSE: Major shortcomings of traditional mouse models based on...*4th October, 2008  
Department of Neurosurgery, University Medical Center Hamburg-Eppendorf,- Clin Cancer Res. 2008 Sep 1;14(17):5447-58. ([DOI Direct Link](#))
- [Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth.](#)  
*PURPOSE: The Aurora kinase family plays pivotal roles in mitotic integrity...*4th October, 2008  
Department of Gynecologic Oncology, The University of Texas M. D. Anderson- Clin Cancer Res. 2008

- Sep 1;14(17):5437-46. ([DOI Direct Link](#))
- [Matuzumab short-term therapy in experimental pancreatic cancer: prolonged antitumor activity in combination with gemcitabine.](#)  
*PURPOSE: The epidermal growth factor receptor ErbB-1 is commonly expressed...*4th October, 2008  
Department of Surgery, Klinikum Grosshadern, Ludwig-Maximilian-University,- Clin Cancer Res. 2008 Sep 1;14(17):5426-36. ([DOI Direct Link](#))
  - [Centrosomal PKCbeta1 and pericentrin are critical for human prostate cancer growth and angiogenesis.](#)  
*Angiogenesis is critical in the progression of prostate cancer. However,...*3rd October, 2008  
Department of Chemical and Systems Biology, Stanford University, School of- Cancer Res. 2008 Aug 15;68(16):6831-9. ([DOI Direct Link](#))
  - [Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model.](#)  
*Herein, using transgenic adenocarcinoma of the mouse prostate (TRAMP)...*3rd October, 2008  
Department of Pharmaceutical Sciences, School of Pharmacy, University of- Cancer Res. 2008 Aug 15;68(16):6822-30. ([DOI Direct Link](#))
  - [Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.](#)  
*Bortezomib, a proteasome inhibitor, has been clinically approved for the...*3rd October, 2008  
Department of Medical Research, National Taiwan University Hospital and- Cancer Res. 2008 Aug 15;68(16):6698-707. ([DOI Direct Link](#))
  - [Neuronal system-dependent facilitation of tumor angiogenesis and tumor growth by calcitonin gene-related peptide.](#)  
*A neuropeptide, calcitonin gene-related peptide (CGRP), is widely...*1st October, 2008  
Departments of Pharmacology and Anesthesiology, Kitasato University School- Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13550-5. Epub 2008 Aug 29. ([DOI Direct Link](#))
  - [Effects of palifermin on antitumor activity of chemotherapeutic and biological agents in human head and neck and colorectal carcinoma xenograft models.](#)  
*Damage to the gastrointestinal mucosa is a common dose-limiting toxicity...*27th September, 2008  
Hematology and Oncology Research, Amgen, Inc., 1201 Amgen Court West,- Mol Cancer Res. 2008 Aug;6(8):1337-46. ([DOI Direct Link](#))
  - [Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice.](#)  
*Although conditionally replicable adenovirus (CRAAd) has been used in the...*24th September, 2008  
Fourth Department of Internal Medicine, Sapporo Medical University, School- Hepatology. 2008 Sep;48(3):828-40. ([DOI Direct Link](#))
  - [Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents \(CA4P or OXi4503\).](#)  
*BACKGROUND: This study evaluated the therapeutic efficacy of combining...*17th September, 2008  
Department of Radiation Oncology, University of Florida College of- Anticancer Res. 2008 Jul-Aug;28(4B):2027-31.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:  
Peter Barfoot Managing Director, BioPortfolio Ltd.  
UK Tel: (+44) 1300 321501  
USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

